The two dermatology products were purchased from an organisation within the Dermapharm Group.

Kelso Pharma is growing through a blend of company and product acquisitions, partnerships and organic growth initially in the UK but seeking to expand its business into the rest of Europe.

Since its inception in 2020, the company has taken a number of positive steps to grow the business in an effective and sustainable manner, positively impacting patients and their families. The acquisition of Glasgow-based Stirling Anglian Pharmaceuticals (SAP) in January 2022 provided a new UK platform and a springboard for future sales growth for the business.

Dr Tom Stratford, CEO at Kelso Pharma, said: “This exciting acquisition signifies another important milestone, not just for our team at Kelso Pharma, but most importantly for patients.

“Launching into the specialty of Dermatology allows us to reach more patients across a number of regions as we continue to grow our business.

“Our team continues to work hard to create collaborative partnerships and identify further potential opportunities to expand our portfolio.”